Oral Third-Generation Cephalosporins for Community-Acquired Pneumonia
For outpatient community-acquired pneumonia, cefpodoxime 200 mg twice daily or cefuroxime 500 mg twice daily are the recommended oral third-generation cephalosporins, always combined with a macrolide (azithromycin or clarithromycin) or doxycycline. 1
Specific Recommendations by Clinical Context
For Previously Healthy Outpatients WITHOUT Comorbidities
The 2019 ATS/IDSA guidelines do NOT recommend third-generation cephalosporins as first-line therapy. Instead, use:
- Amoxicillin 1 g every 8 hours (preferred), OR
- Doxycycline 100 mg twice daily 1
Third-generation cephalosporins are reserved for patients with specific risk factors.
For Outpatients WITH Comorbidities or Risk Factors
When third-generation cephalosporins are indicated, use combination therapy:
Cephalosporin options:
- Cefpodoxime 200 mg twice daily, OR
- Cefuroxime 500 mg twice daily
PLUS one of:
- Azithromycin 500 mg day 1, then 250 mg daily (strong recommendation), OR
- Clarithromycin 500 mg twice daily or extended-release 1,000 mg once daily (strong recommendation), OR
- Doxycycline 100 mg twice daily (conditional recommendation) 1
Alternative: Monotherapy with Respiratory Fluoroquinolone
Instead of cephalosporin combination therapy, you can use:
- Levofloxacin 750 mg daily, OR
- Moxifloxacin 400 mg daily, OR
- Gemifloxacin 320 mg daily 1
Additional Third-Generation Cephalosporin Options
While not specifically mentioned in the primary guideline recommendations, cefdinir is another oral third-generation cephalosporin with documented efficacy:
- Cefdinir 300 mg twice daily or 600 mg once daily for 5-10 days 2, 3
- Good activity against H. influenzae, M. catarrhalis, and penicillin-susceptible S. pneumoniae
- Stable against beta-lactamase-producing strains
Cefixime 400 mg once daily has been studied for step-down therapy after initial IV treatment 4, though it is not included in current guideline recommendations for initial outpatient therapy.
Critical Caveats
Never use third-generation cephalosporins as monotherapy for CAP. The 2007 IDSA/ATS guidelines explicitly list oral cephalosporins (cefpodoxime, cefprozil, cefuroxime, cefdinir, cefditoren) as alternatives to penicillin for S. pneumoniae, but the 2019 update emphasizes combination therapy when cephalosporins are used empirically 1, 5.
Comorbidities requiring cephalosporin consideration include:
- Chronic heart, lung, liver, or renal disease
- Diabetes mellitus
- Alcoholism
- Malignancy
- Asplenia 1
Duration of Therapy
- 5 days is sufficient for most cases of CAP when clinical improvement occurs 6
- Reassess at 72 hours after starting antibiotics 6
Comparative Evidence
Recent evidence suggests that amoxicillin-clavulanate is not inferior to third-generation cephalosporins (ceftriaxone/cefotaxime) for hospitalized patients with community-onset pneumonia 7. This supports the guideline preference for amoxicillin-based regimens in appropriate patients, reserving cephalosporins for specific indications.